Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
STAAR Surgical Company (NASDAQ: STAA) features prominently in ophthalmic and corporate news due to its focus on implantable intraocular lenses and its role in the vision correction market. Company press releases describe STAAR as the global leader in implantable phakic intraocular lenses, particularly through the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, and as a long-standing participant in ophthalmic surgery since 1982.
This news page aggregates coverage related to STAAR’s product developments, strategic decisions, shareholder actions, and governance changes. Recent announcements include the proposed and later terminated merger agreement with Alcon, a series of special meetings and proxy solicitations, and a cooperation agreement with major shareholder Broadwood Partners under which representatives of Broadwood and Yunqi Capital joined STAAR’s Board of Directors. These events illustrate how transaction activity and shareholder perspectives can influence the company’s direction while it continues to operate as a standalone, publicly traded company on Nasdaq.
Readers can expect updates on topics such as merger and acquisition proposals, outcomes of shareholder votes, board appointments, and other material events reported in STAAR’s press releases and related communications. Because STAAR’s core business centers on ophthalmic surgical products like Implantable Collamer Lenses and intraocular lenses, news may also highlight the positioning of its EVO ICL technology and its use in vision correction procedures in markets around the world.
For investors, analysts, and industry observers, following STAA news offers insight into both the company’s ophthalmic product strategy and its evolving governance and ownership dynamics. This page provides a centralized view of those developments as they are reported in official company and market communications.
STAAR Surgical has opened its first EVO Experience Center at its headquarters in Lake Forest, California, aimed at enhancing training and education for ophthalmic surgeons. The facility features advanced technology for in-person and virtual training, including a surgical simulation room. The grand opening on November 10 was attended by notable guests including fashion model India Gants. This initiative seeks to boost interest and adoption of the EVO ICL globally, with more than 2 million ICLs sold across 75 countries.
STAAR Surgical Company (STAA) reported Q3 2022 net sales of $76 million, up 30% from the prior year. Constant currency net sales hit $80 million, reflecting a 37% increase. ICL sales accounted for $72 million, a 33% rise, with units sold up 40%. Gross margin improved to 79.5%, and net income per share rose to $0.21. Despite robust growth, the company anticipates challenges in Q4 due to COVID restrictions in China, forecasting total 2022 net sales near $285 million. STAAR emphasizes focus on its premium EVO products while facing supply chain issues in its low-margin Other Products segment.
STAAR Surgical Company (NASDAQ: STAA) announced it will release its third-quarter financial results on November 2, 2022, after market close. A conference call will follow at 4:30 p.m. Eastern to discuss the results and operational progress. Investors can access the call by dialing 844-200-6205 for domestic calls. The company, a leader in implantable lenses for ophthalmic surgery, has sold over 2 million ICLs globally. It operates facilities in California and Switzerland, emphasizing innovation in visual freedom solutions.
STAAR Surgical partners with professional basketball player Max Strus to promote its EVO Implantable Collamer® Lenses, aimed at addressing myopia, affecting over 2 billion globally. Strus recently underwent the EVO procedure for enhanced vision, achieving better than 20/20 clarity. The collaboration aims to raise awareness about the EVO lens as a non-invasive vision correction option. The company highlights that myopia's prevalence is expected to reach 50% of the global population by 2050, emphasizing the need for effective solutions.
STAAR Surgical Company (NASDAQ: STAA) hosted a media day in NYC featuring singer Joe Jonas, who shared his positive experience with EVO Visian® Implantable Collamer® Lenses. Since the FDA approval on March 25, 2022, STAAR has focused on educating potential patients about EVO. To enhance visibility, an omni-channel advertising campaign will begin later this month, showcasing Jonas' journey and patient satisfaction. Additionally, certified surgeons are actively promoting EVO on social media, and new patient ambassadors will join in the outreach efforts.
STAAR Surgical Company (NASDAQ: STAA) has partnered with Joe Jonas for a global campaign to promote its EVO Visian® Implantable Collamer® Lenses (EVO), designed to correct myopia and astigmatism. Recently, Jonas underwent the EVO procedure, achieving visual freedom from glasses and contact lenses. The campaign, launching in September 2022, aims to educate Americans about EVO, which has been successfully implanted worldwide and boasts a high satisfaction rate among patients. EVO lenses offer clarity, UV protection, and are removable if needed.
STAAR Surgical Company (NASDAQ: STAA) reported record net sales of $81.1 million for Q2 2022, up 30% from last year. Constant currency net sales reached $84.2 million, showing a 35% increase. The company achieved a gross margin of 78.8% and net income of $0.26 per share, up from $0.17 per share in the prior year. ICL sales, which made up 96% of total sales, increased by 32%. Despite foreign currency headwinds impacting sales by $3.1 million, STAAR reaffirmed its 2022 net sales outlook of approximately $295 million, driven by strong demand for EVO lenses.
STAAR Surgical Company (NASDAQ: STAA) is set to release its Q2 2022 financial results on August 10, 2022, after market close. The company will host a conference call and webcast the same day at 4:30 p.m. Eastern. This conference will cover financial results and operational updates. STAAR has specialized in ophthalmic surgery for over 40 years, marketing foldable implantable lenses, notably the Visian ICL, with over 2 million units sold worldwide.
Summary not available.
STAAR Surgical Company (NASDAQ: STAA) announced record financial results for Q1 2022, with net sales reaching $63.2 million, a 25% increase year-over-year. ICL sales accounted for $58.7 million of this total, marking a 26% growth. The company reported a gross margin of 77.9% and net income of $9.6 million ($0.19 per share), up from $5.0 million ($0.10 per share) a year earlier. STAAR also highlighted strong global growth, particularly in China, Japan, and India, and reaffirmed its annual sales outlook of approximately $295 million, a 28% increase from the previous year.
FAQ
What is the current stock price of Staar Surg (STAA)?
What is the market cap of Staar Surg (STAA)?
